Long-term goals in the treatment of chronic graft-versus-host disease after matched allogeneic hematopoietic stem cell transplantation

Moiseev, Ivan S.; Dotsenko, Anna A.; Smirnova, Anna; Vlasova, Yulia; Morozova, Elena; Bondarenko, Sergey N.; Afanasyev, Boris

doi:10.18620/ctt-1866-8836-2020-9-4-29-36

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В исследуемой группе пациентов большая часть (93,7%) имела хроническую РТПХ, и все пациенты на момент развития COVID19 получали иммуносу прессивную терапию, что является обязательным ус ловием благоприятного исхода хрРТПХ [11]. С одной стороны, в этой группе COVID19 был зарегистриро ван в поздний период с медианой времени 372,5 дней (47-3490) после аллоТГСК, что могло бы повлиять на прогноз, как было продемонстрировано Sharma A. и соавт.…”

Section: Discussionunclassified

Untitled

2022

CMAC

View full text Add to dashboard Cite

Межрегиональная ассоци ация по клинической микро био логии и антимикробной химиотерапии Научноисследовательский ин ститут антимикробной химио терапии ФГБОУ ВО СГМУ Минздрава России Учредитель Межрегиональная ассоциа ция по клинической микро биоло гии и анти мик роб ной химио терапии Издатель Межрегиональная ассоциа ция по клинической микро био логии и антимикроб ной химиотерапии www.iacmac.ru Журнал зарегистрирован Комитетом РФ по печати 30.09.1999 г. (№019273) Тираж 3000 экз. Подписка на сайте издателя https://service.iacmac.ru Адрес для корреспонденции 214019, г. Смоленск, а/я 5. Тел./факс: (4812)45 06 02

show abstract

Section: Discussionunclassified

Untitled

2022

CMAC

View full text Add to dashboard Cite

show abstract

Diagnosis and staging of ophthalmic manifestations of the graft-versus-host reaction after allogeneic hematopoietic stem cell transplantation

Chistyakova

2021

Ophthalmology Reports

View full text Add to dashboard Cite

Graft-versus-host reaction is a common complication of allogeneic hematopoietic stem cell transplantation. This condition develops in approximately 4070% of patients. Its most common clinical manifestations include xerotic keratoconjunctivitis and cicatricial conjunctivitis. It is important to correctly diagnose and classify the ocular condition after surgery. Ocular graft-versus-host reaction can present as either classic acute or chronic form, acute form with late onset or with overlap syndrome. It may lead to severe ocular surface disease, which can significantly decrease the quality of life and restrict daily activities of patients. It is thus important to monitor the ocular condition closely since with early diagnosis of the condition and timely treatment start, risks of irreversible damage could be diminished. This article is dedicated to modern criteria of diagnosis and staging of ocular graft-versus-host reaction.

show abstract

COVID-19 infection in hematopoietic stem cell transplant recipients

Siniaev

Grinenko

Popova

et al. 2022

CMAC

View full text Add to dashboard Cite

Objective. To assess the course and outcomes of COVID-19 in recipients of allogeneic and autologous hematopoietic stem cell transplant (HSCT). Materials and Methods. The retrospective study included 44 adult recipients (allogeneic – 33 [75%] and autologous – 11 [25%] of HSCT who diagnosed with COVID-19 after transplantation. Group mostly represented by acute leukemia – 18 (41%) and lymphoma – 10 (22.7%). The median follow-up time since the development of COVID-19 was 231 days (1–818 days), after HSCT – 507.5 days (14–3723 days). Overall and progression-free survival was assessed using the Kaplan–Meier and Log-Rank method. We also evaluated the characteristics of the course of a new coronavirus infection. Results. Median time for the development of COVID-19 from the moment of HSCT was 122.5 days (-1–3490 days). Twelve patients (27.2%) were in grade 3–4 neutropenia at the time of COVID-19 diagnosis, 16 (36.4%) patients were in grade 1–2 neutropenia. Sixteen (48.4%) allo-HSCT recipients had active graft-versus-host disease (GVHD) at the time of COVID-19 development. Disease severity was mild in 19 (43.2%) and moderate in 13 (29.5%) patients. Overall, 200-day survival from the onset of COVID-19 was 78.8% (95% CI [63.1–88.4]). Anemia (p = 0.02) and thrombocytopenia (p = 0.01) significantly decrease OS in patients with COVID-19 after HSCT. Patients with GVHD at the time of COVID-19 onset had a better survival rate (p = 0.02). The timing of COVID-19 development after HSCT did not affect outcomes. Conclusions. The key points of the course of COVID-19 in HSCT recipients are the presence of cytopenia and graft-versus-host disease. Overall survival was 78.8%.

show abstract

Long-term goals in the treatment of chronic graft-versus-host disease after matched allogeneic hematopoietic stem cell transplantation

Abstract: Long-term goals in the treatment of chronic graft-versus-host disease after matched allogeneic hematopoietic stem cell transplantation

Cited by 3 publications

References 28 publications

Untitled

Untitled

Diagnosis and staging of ophthalmic manifestations of the graft-versus-host reaction after allogeneic hematopoietic stem cell transplantation

COVID-19 infection in hematopoietic stem cell transplant recipients

Contact Info

Product

Resources

About